Pineda-Belmontes Cristina P, Hernández-Ramírez Raúl U, Hernández-Alcaraz César, Cebrián Mariano E, López-Carrillo Lizbeth
Salud Publica Mex. 2016 Apr;58(2):220-7. doi: 10.21149/spm.v58i2.7791.
To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC).
Mexican women were interviewed, and blood and urine samples were collected from them (cases/controls= 197/220). The concentration of urinary arsenic species and the polymorphisms of interest were determined by high-performance liquid chromatography with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) and polymerase chain reaction (PCR), respectively.
In women with a high %MMA (urinary monomethyl arsenic) and high primary methylation ratio (PM = MMA/iAs), the risk of BC was increased (odds ratio [OR]%MMA T3 vs.T1= 3.60: 95% confidence interval [CI] 2.02-6.41, ORPMI T3 vs.T1= 3.47: 95%CI 1.95-6.17), which was maintained after adjusting for polymorphisms. No significant interactions were observed between the polymorphisms and the arsenic variables on the risk of BC.
Pro 12Ala and Ala203Pro polymorphisms did not modify the association between the iAs methylation capacity and BC.
评估过氧化物酶体增殖物激活受体γ（PPARγ）（Pro12Ala）和PPARGC1B（Ala203Pro）基因多态性的存在是否会改变无机砷（iAs）甲基化能力与乳腺癌（BC）之间的关联。
对墨西哥女性进行访谈，并采集她们的血液和尿液样本（病例/对照 = 197/220）。分别采用电感耦合等离子体质谱联用高效液相色谱法（HPLC-ICP-MS）和聚合酶链反应（PCR）测定尿砷形态浓度和相关基因多态性。
在尿一甲基砷（MMA）百分比高且初级甲基化率（PM = MMA/iAs）高的女性中，患BC的风险增加（比值比[OR]%MMA T3与T1相比 = 3.60：95%置信区间[CI] 2.02 - 6.41，ORPMI T3与T1相比 = 3.47：95%CI 1.95 - 6.17），在对基因多态性进行校正后该风险依然存在。未观察到基因多态性与砷变量之间在BC风险上存在显著相互作用。
Pro12Ala和Ala203Pro基因多态性并未改变iAs甲基化能力与BC之间的关联。
